Annabel Samimy
Stock Analyst at Stifel
(4.50)
# 280
Out of 5,152 analysts
57
Total ratings
49.06%
Success rate
41.41%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Annabel Samimy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OCS Oculis Holding AG | Maintains: Buy | $40 → $50 | $28.06 | +78.19% | 3 | Mar 5, 2026 | |
| EOLS Evolus | Maintains: Buy | $20 → $17 | $5.77 | +194.63% | 2 | Jan 13, 2026 | |
| TRVI Trevi Therapeutics | Maintains: Buy | $15 → $18 | $12.91 | +39.43% | 1 | Dec 19, 2025 | |
| SUPN Supernus Pharmaceuticals | Maintains: Hold | $50 → $55 | $53.85 | +2.14% | 8 | Dec 19, 2025 | |
| RGNX REGENXBIO | Maintains: Buy | $40 → $45 | $8.40 | +435.71% | 3 | Dec 19, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $45 → $52 | $27.73 | +87.52% | 2 | Dec 19, 2025 | |
| MBX MBX Biosciences | Maintains: Buy | $45 → $50 | $31.49 | +58.78% | 2 | Dec 19, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $55 → $48 | $20.47 | +134.49% | 4 | Dec 19, 2025 | |
| LGND Ligand Pharmaceuticals | Maintains: Buy | $220 → $230 | $200.78 | +14.55% | 2 | Dec 10, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $50 → $90 | $60.50 | +48.76% | 2 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $87 → $145 | $135.65 | +6.89% | 3 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $3.99 | +351.69% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $17 | $6.17 | +175.53% | 4 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $8.98 | +100.45% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $11.22 | +113.90% | 1 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $80 | $30.73 | +160.33% | 6 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $225 → $230 | $185.01 | +24.32% | 8 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $1.32 | +1,718.18% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $700 → $750 | $2.21 | +33,842.80% | 3 | Apr 16, 2020 |
Oculis Holding AG
Mar 5, 2026
Maintains: Buy
Price Target: $40 → $50
Current: $28.06
Upside: +78.19%
Evolus
Jan 13, 2026
Maintains: Buy
Price Target: $20 → $17
Current: $5.77
Upside: +194.63%
Trevi Therapeutics
Dec 19, 2025
Maintains: Buy
Price Target: $15 → $18
Current: $12.91
Upside: +39.43%
Supernus Pharmaceuticals
Dec 19, 2025
Maintains: Hold
Price Target: $50 → $55
Current: $53.85
Upside: +2.14%
REGENXBIO
Dec 19, 2025
Maintains: Buy
Price Target: $40 → $45
Current: $8.40
Upside: +435.71%
Mineralys Therapeutics
Dec 19, 2025
Maintains: Buy
Price Target: $45 → $52
Current: $27.73
Upside: +87.52%
MBX Biosciences
Dec 19, 2025
Maintains: Buy
Price Target: $45 → $50
Current: $31.49
Upside: +58.78%
Apellis Pharmaceuticals
Dec 19, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $20.47
Upside: +134.49%
Ligand Pharmaceuticals
Dec 10, 2025
Maintains: Buy
Price Target: $220 → $230
Current: $200.78
Upside: +14.55%
Structure Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $50 → $90
Current: $60.50
Upside: +48.76%
Nov 24, 2025
Maintains: Buy
Price Target: $87 → $145
Current: $135.65
Upside: +6.89%
Jan 8, 2025
Initiates: Buy
Price Target: $18
Current: $3.99
Upside: +351.69%
Nov 22, 2024
Maintains: Buy
Price Target: $20 → $17
Current: $6.17
Upside: +175.53%
Jul 3, 2024
Initiates: Buy
Price Target: $18
Current: $8.98
Upside: +100.45%
May 3, 2024
Initiates: Buy
Price Target: $24
Current: $11.22
Upside: +113.90%
Mar 15, 2024
Reiterates: Buy
Price Target: $80
Current: $30.73
Upside: +160.33%
Mar 15, 2024
Maintains: Buy
Price Target: $225 → $230
Current: $185.01
Upside: +24.32%
Aug 24, 2021
Initiates: Buy
Price Target: $24
Current: $1.32
Upside: +1,718.18%
Apr 16, 2020
Maintains: Buy
Price Target: $700 → $750
Current: $2.21
Upside: +33,842.80%